- BTIG increased its price target for Cullinan Therapeutics to $40, suggesting a potential upside of approximately 93% from its current stock price.
- This positive outlook stems from successful Phase 3 REZILIENT3 trial results for zipalertinib, a key therapy for non-small cell lung cancer, which met its primary endpoint.
- The trial demonstrated a clinically meaningful improvement of 6.0 months in progression-free survival for patients, highlighting the therapy’s efficacy.
BTIG recently raised its price target for Cullinan Therapeutics (NASDAQ: CGEM) to $40 from a previous target of $39. Cullinan Therapeutics is a biopharmaceutical company that develops targeted therapies for cancer patients. This new price target suggests a potential upside of approximately 93% from the stock’s price of $20.73 at the time of the announcement.
The updated price target follows positive results from the Phase 3 REZILIENT3 trial. The study evaluated zipalertinib with chemotherapy as a first-line treatment for a specific type of non-small cell lung cancer. As highlighted by GuruFocus, Cullinan Therapeutics announced the trial successfully met its main goal, driving positive sentiment.
The study demonstrated a clinically meaningful median progression-free survival (PFS) improvement of 6.0 months. Progression-free survival measures the length of time a patient lives with a disease without it getting worse. This result was achieved when zipalertinib was added to standard chemotherapy for these lung cancer patients.
To discuss these findings, Cullinan Therapeutics hosted a virtual event for analysts and investors on September 14, 2026, as reported by GlobeNewswire. The data was initially presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference, a major event in the field of oncology.
Reflecting recent activity, Cullinan Therapeutics stock is trading at $20.85, with a day’s range between $18.51 and $20.86. The company’s market capitalization, which is the total value of all its shares, stands at approximately $1.28 billion. The stock’s 52-week high is $23.19, showing its recent upward movement.
